Vimta Labs Ltd.

VIMTALABS

Market Cap
₹1,219 Cr.
P/E
29.68

Vimta Labs Ltd.

About
Vimta Labs Limited, established in 1984, provides analytical, clinical, preclinical services to life sciences industries, quality testing for food and beverage sectors, and environment services to var… Read more
Vimta Labs Limited, established in 1984, provides analytical, clinical, preclinical services t… Read more
Low
390
52W Range
High
623
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics

9 Yes

Positive for this company

1 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
12.83%
3yr Average
15.86%
5yr Average
12.51%
Net Profit Margin
Latest
12.89%
3yr Average
14.29%
5yr Average
11.36%
ROCE
Latest
16.74%
3yr Average
20.64%
5yr Average
16.47%
Debt to Equity
Latest
0.06
3yr Average
0.07
5yr Average
0.11
Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    locked
    Select a Metric
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    FAQs on Vimta Labs Ltd. Business

    Founded in 1984, Vimta Labs Limited provides analytical, clinical, and preclinical services to life sciences industries, quality testing for food and beverage sectors, and environmental services globally.

    Vimta Labs major competitors are Krsnaa Diagnostics, Nidan Labs. & Health, Thyrocare Tech., Vijaya Diagnostic, Metropolis Health., Dr. Lal Pathlabs, Max India.
    Market Cap of Vimta Labs is ₹1,219 Crs.
    While the median market cap of its peers are ₹4,124 Crs.

    Vimta Labs seems to be financially stable compared to its peers.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate peers.

    Company Filing
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Jun Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Jun Mar Jun Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis
    Vimta Labs Ltd.
    View the discussion on ValuePickr
    Vimta Labs Ltd – Bet on the emerging theme of Contract Research & Testing Outsourcing - SOC Invest
    Diagnostics
    How The Diagnostics Industry Works - PPFAS
    Diagnostic Industry - P2P Analysis - SOIC
    Impact on compeitition like TATA1MG on Diagnostics Sector - Aditya Khemka(Incred) - Bloomberg Quint
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline Timeline